
|Articles|March 1, 2003
Multifaceted Topical
Pittsburgh -Topical tacrolimus ointment 0.1 percent (Protopic) may be a viable addition to the current therapeutic armamentarium for early-stage cutaneous T-cell lymphoma (CTCL), Larisa Geskin, M.D., said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














